ArticleJornal brasileiro de nefrologia
Anti-PLA2R antibody reduction as a predictor of treatment response in primary membranous nephropathy: a retrospective study.
Article in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-PLA2R antibodies: implications for therapeutic planning and the prediction of remission in membranous nephropathy.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary membranous nephropathy (PMN) is a leading cause of nephrotic syndrome in adults. Although proteinuria has been the conventional guiding parameter in disease monitoring, its limitations as a non-specific and delayed marker have led to the appeal of anti-phospholipase A2 receptor antibodies (PLA2R) as specific and sensitive indicators of disease activity and response to treatment.
methodsThis retrospective cohort study included 60 patients with biopsy-proven PMN and positive baseline anti-PLA2R antibodies who underwent treatment at the Multan Institute of Kidney Diseases. Anti-PLA2R levels were measured at baseline and at the 6-month follow-up using enzyme-linked immunosorbent assay (ELISA). Clinical remission was assessed using the standard proteinuria and renal function criteria. Statistical analyses included receiver operating characteristic (ROC) curves, logistic regression, and correlation assessments.
resultsBaseline anti-PLA2R levels were significantly lower in patients who achieved remission (p = 0.047), and 6-month levels showed a strong correlation with treatment response (p < 0.001). ROC analysis demonstrated good predictive accuracy with area under curve (AUC) of 0.707 (baseline) and 0.815 (6-month), identifying optimal remission cutoffs at 125.5 RU/mL and 37.75 RU/mL, respectively. Logistic regression analysis confirmed the baseline albumin level, 6-month anti-PLA2R, and proteinuria reduction as independent predictors of remission.
conclusionAnti-PLA2R antibody levels at baseline and 6 months serve as robust predictors of treatment response in PMN and outperform proteinuria in early remission assessment. These findings support the integration of anti-PLA2R monitoring into standard clinical practice for personalized management and therapy adjustment in PMN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.